Inland Northwest Research

Spokane, Washington 99204

7 studies enrolling now · 37 studies all time

What they study most

Alzheimer Disease, Deep Brain Stimulation, Dementia With Lewy Bodies (DLB), Dystonia, Early Parkinson Disease (Early PD), Essential Tremor, GBA1 Parkinson Disease, Healthy Participants, Huntington Disease, Idiopathic Parkinson Disease, MSA, Movement Disorders

Studies at this site

• Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease — Recruiting now
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Recruiting now
• A Study of Buntanetap in Participants With PD — Recruiting now
• Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry — Recruiting now
• A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease — Recruiting now
• Parkinson's Foundation PD GENEration Genetic Registry — Recruiting now
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease — Withdrawn before enrolling
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• A Study of TAK-341 in Treatment of Multiple System Atrophy — Completed
• Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) — Running, not enrolling
• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Running, not enrolling
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Running, not enrolling
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study — Available (expanded access)
• Rostock International Parkinson's Disease Study (ROPAD) — Completed
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease — Completed
• STEM-Parkinson's Disease — Completed
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD — Completed
• A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD — Completed
• A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling — Completed
• A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis — Completed
• A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale — Stopped early
• A Study of TAK-071 in People With Parkinson Disease — Completed
• A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia — Completed
• Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies — Completed
• NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa — Completed
• Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early
• Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early
• Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD — Status unconfirmed
• Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Completed
• Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool — Completed
• Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease — Stopped early
• Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression — Completed
• Study of Urate Elevation in Parkinson's Disease, Phase 3 — Completed
• Nilotinib in Parkinson's Disease — Completed